Stock Analiz

BeyondSpring Inc. BYSI

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$0.60Market cap $25M
Open the interactive analysis →

BeyondSpring Inc. (BYSI) is a healthcare company listed in the US with a market value of about $25M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -173%.

About BeyondSpring

BeyondSpring is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data.

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-67.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3606.9%
ROIC (5-yr avg.)-172.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$0$0$1M$1M$180000$0$0$0$0
Net income-$1M-$11M-$21M-$33M-$64M-$61M-$38M-$55M-$92M-$12M
Free cash flow-$20M-$17M-$17M-$27M-$50M-$44M-$48M-$40M-$29M-$14M
EPS (diluted)$-0.02$-0.27$-0.51$-0.81$-1.56$-1.48$-0.93$-1.33$-2.23$-0.29
Net margin———-2463.3%-4750.5%-33873.9%————
ROIC————-172.9%-69.3%-117.9%—-285.9%-80.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does BeyondSpring pay a dividend?

Not currently.

Is BeyondSpring a good stock to buy?

We do not give buy or sell advice. BeyondSpring scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.